LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation Rainer Kraehenmann, Dan Pokorny, Helena Aicher, Katrin H. Preller, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz and Franz X. Vollenweider Frontiers in Pharmacology, 2017, Volume 8, Article 814, 1-9. Doi : 10.3389/fphar.2017.00814 Rationale : Stimulation of serotonin 2A (5-HT2A) receptors by lysergic acid diethylamide (LSD) and related compounds such as psilocybin has previously been shown to increase primary process thinking – an ontologically and evolutionary early, implicit, associative, and automatic mode of thinking which is typically occurring during altered states of consciousness such as dreaming. However, it is still largely unknown whether LSD induces [...]
Lire la suiteAvec le confinement: beaucoup de syndromes de manque Benjamin ROLLAND https://www.addictolyon.fr/post/avec-le-confinement-beaucoup-de-syndromes-de-manque Addictolyon, 19/03/2020, Mis à jour : il y a 4 jours Avec le #confinement lié au #COVID19, les trafics de substances semblent s'être fortement réduits. Résultat: en ville, à l'hôpital, en prison, de nombreux syndromes de manque apparaissent. Afin de faciliter la reconnaissance et la prise en charge des syndrome de sevrage chez les patients, voici un petit document explicatif du repérage et du traitement des syndrome de sevrage à catégories importantes de substance: #tabac, #cannabis, et #opioïdes
Lire la suiteA Comparative Literature Survey of Psilocybin and LSD-25 Metabolism Ian Joyce Capstone Project CHM 400 H Cal Poly Pomona, Winter 2017 | 1 - &ç Psilocybin and lysergic acid diethylamide (LSD-25) are two of the most popular and well known psychedelic drugs. Although both of the compounds are currently illegal in the United States, a renewed interest has begun in recent years to examine and analyze these drugs for therapeutic use. This review analyzes the current research pertaining to the metabolism, biochemical pathways, receptor activity, biological signaling, physiological effects and the behavioral effects associated with both of these compounds. For psychedelic compounds to [...]
Lire la suiteCannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches Marcel O. Bonn-Miller, Mahmoud A. ElSohly, Mallory J. E. Loflin, Suman Chandra and Ryan Vandrey International Review of Psychiatry, 2018, VOL. 30, NO. 3, 277–284 Doi : 10.1080/09540261.2018.1474730 ABSTRACT Accumulating evidence suggests that the endocannabinoid system is a promising target for the treatment of a variety of health conditions. Two paths of cannabinoid drug development have emerged. One approach is focused on developing medications that are directly derived from the cannabis plant. The other utilizes a single molecule approach whereby individual phytocannabinoids or novel cannabinoids with therapeutic potential are identified and synthesized for pharmaceutical [...]
Lire la suiteCANNABIDIOL (CBD), Pre-Review Report, Agenda Item 5.2 Expert Committee on Drug Dependence Thirty-ninth Meeting, Geneva, 6-10 November 2017 39th ECDD (2017) Agenda item 5.2 Cannabidiol (CBD) Contents Acknowledgements .................................................................................................................. 4 Summary ................................................................................................................................... 5 1. Substance identification ........................................................................................................ 6 A. International Nonproprietary Name (INN) .......................................................................... 6 B. Chemical Abstract Service (CAS) Registry Number .............................................................. 6 C. Other Chemical Names .......................................................................................................... 6 D. Trade Names .......................................................................................................................... 6 E. Street Names .......................................................................................................................... 6 F. Physical Appearance .............................................................................................................. 6 G. WHO Review History ............................................................................................................. 6 2. Chemistry ............................................................................................................................... 6 A. Chemical Name ...................................................................................................................... 6 B. Chemical Structure ................................................................................................................. 7 C. Stereoisomers ......................................................................................................................... 7 D. Methods and Ease of Illicit Manufacturing ............................................................................ 7 E. Chemical Properties ............................................................................................................... 9 F. Identification and Analysis ..................................................................................................... 9 3. Ease of [...]
Lire la suiteCannabidiol for Viral Diseases : Hype or Hope ? Alex Mabou Tagne, Barbara Pacchetti, Mikael Sodergren, Marco Cosentino, and Franca Marino Cannabis and Cannabinoid Research, 2020,1-11. Doi : 10.1089/can.2019.0060 Abstract Background : The possibility of cannabidiol (CBD) to be used as an antiviral or to treat viral diseases has received limited attention so far, despite the growing number of claims that CBD could be used for the treatment of viral infection-related conditions. Aim and Methods : Therefore, we systematically retrieved and critically evaluated the scientific literature available on PubMed and the claims on the Internet, to assess the current state of knowledge on the use of [...]
Lire la suiteBibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, mars 2020. voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives
Lire la suiteUse of Cannabidiol for the Treatment of Anxiety : A Short Synthesis of Pre-Clinical and Clinical Evidence Madison Wright, Patricia Di Ciano, and Bruna Brands Cannabis and Cannabinoid Research, 2019, Volume X, Number X, 1-6. Doi : 10.1089/can.2019.0052 Abstract Anxiety disorders have the highest lifetime prevalence of any mental illness worldwide, leading to high societal costs and economic burden. Current pharmacotherapies for anxiety disorders are associated with adverse effects and low efficacy. Cannabidiol (CBD) is a constituent of the Cannabis plant, which has potential therapeutic properties for various indications. After the recent legalization of cannabis, CBD has drawn increased attention as a potential treatment, as [...]
Lire la suiteDown-Regulation of Cannabinoid Type 1 (CB1) Receptor and its Downstream Signaling Pathways in Metastatic Colorectal Cancer Valeria Tutino, Maria Gabriella Caruso, Valentina De Nunzio, Dionigi Lorusso, Nicola Veronese, Isabella Gigante, Maria Notarnicola and Gianluigi Giannelli Cancers, 2019, 11, 708, 1-14. doi :10.3390/cancers11050708 Abstract : Changes in the regulation of endocannabinoid production, together with an altered expression of their receptors are hallmarks of cancer, including colorectal cancer (CRC). Although several studies have been conducted to understand the biological role of the CB1 receptor in cancer, little is known about its involvement in the metastatic process of CRC. The aim of this study was to investigate the [...]
Lire la suiteNonlinear Disposition and Metabolic Interactions of Cannabidiol Through CYP3A Inhibition In Vivo in Rats Michiru Nagao, Yukako Nakano, Masataka Tajima, Erika Sugiyama, Vilasinee Hirunpanich Sato, Makoto Inada, and Hitoshi Sato Cannabis and Cannabinoid Research, 2020, Volume X, Number X, 1-8. DOI: 10.1089/can.2019.0098 Abstract Introduction : Cannabidiol (CBD) is known to affect the pharmacokinetics of other drugs through metabolic inhibition of CYP2C19 and CYP3A4. However, there is a lack of in vivo evidence for such drug interactions. Therefore, we investigated the saturability of CBD metabolism and CBD-drug interactions through inhibition of CYP3A in vivo. Materials and Methods : A nanoemulsion formulation of CBD (CBD-NE) was orally administered to [...]
Lire la suite